There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EphB4


EphB4 Molecule Information

Name:Ephrin type-B receptor 4
Target Synonym:TYRO11;EPHB4;Tyrosine-protein kinase TYRO11;Ephrin type-B receptor 4;MYK1;Hepatoma transmembrane kinase;HTK
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase ?

EphB4 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
EP4-H8229 Human Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling)
EP4-H5229 Human Human EphB4 Protein, His Tag

EphB4 Molecule Synonym Name


EphB4 Molecule Background

Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.

EphB4 References

EphB4 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JI-101 JI-101; CGI-1842 Phase Ⅱ Gilead, Jubilant Innovation Solid tumours Details
sEphB4-HSA Vas-01; sEphB4-HSA Phase Ⅱ VasGene, National Cancer Institute, University of Southern California Solid tumours, Kaposi's sarcoma Details
TG-100801 TG-100801 Phase Ⅱ Sanofi Age-related macular degeneration (AMD) Details
TG-100572 TG-100572 Phase Ⅱ Sanofi Age-related macular degeneration (AMD) Details

This web search service is supported by Google Inc.